As Co-Director of the Center for Immuno-Oncology, Dr. Schlom directs a translational research program in cancer immunology and immunotherapy. He has pioneered the use of novel immunotherapeutics, both as monotherapy and in combination therapies, for a range of human cancers. His studies involve the translation of hypothesis-driven preclinical studies to science-driven clinical trials. Dr. Schlom works closely with clinicians in the CIO and with investigators in multiple Laboratories/Branches of the NCI and NIH, and at extramural Cancer Centers. Dr. Schlom also works closely with investigators in multiple Biotech and Pharma companies, via Cooperative Research and Development Agreements, to rapidly translate preclinical findings into agents for clinical studies. Dr. Schlom’s studies involve the design and development of novel therapeutic cancer vaccines, immunocytokines, checkpoint inhibitor monoclonal antibodies, inhibitors of immune suppressive entities, as well as agents and strategies to modify the tumor microenvironment to render tumor cells more susceptible to immune-mediated therapy.